Traded Sep 14 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Sep 4, 2026 · Filed Sep 4, 2026
A Krystal Biotech director sold $722K of Krystal Biotech shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$722,404
Shares × reported transaction price
32 days after results of Aug 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −4.2% | −1.1% | −3.0% |
Past results only. Not a forecast.
Traded Sep 14 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Sep 14 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Sep 14 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.